A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants
A Phase 1, Randomized, Double-blind, Positive-controlled, Placebo-controlled, 4-Period Crossover, Thorough QT/QTc Study to Evaluate the Effect of Multiple Doses of BMS-986278 on Cardiac Repolarization in Healthy Participants
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: First line of the email MUST contain NCT # and Site #.
Study Contact Backup
- Name: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- Phone Number: 855-907-3286
- Email: Clinical.Trials@bms.com
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78217
- Local Institution - 0001
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Female individuals not of childbearing potential and males.
- Healthy as determined by medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory assessments.
- 18 to 55 years of age, inclusive, at the time of signing the informed consent with a BMI 18.0 to 32.0 kg/m2, inclusive.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treatment B
|
Specified dose on specified days
Specified dose on specified days
|
|
Experimental: Treatment A
|
Specified dose on specified days
|
|
Placebo Comparator: Treatment C
|
Specified dose on specified days
|
|
Experimental: Treatment D
|
Specified dose on specified days
Specified dose on specified days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from baseline Fridericia's corrected QT interval (QTcF) (ΔQTcF)
Time Frame: Up to Day 13
|
Up to Day 13
|
|
Placebo-corrected change from baseline QTcF (ΔΔQTcF)
Time Frame: Up to Day 13
|
Up to Day 13
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Placebo-corrected change from baseline QTcF (ΔΔQTcF)
Time Frame: Up to Day 13
|
Up to Day 13
|
|
Change from baseline heart rate (HR)
Time Frame: Up to Day 13
|
Up to Day 13
|
|
Placebo-corrected change from baseline HR
Time Frame: Up to Day 13
|
Up to Day 13
|
|
Change from baseline PR interval
Time Frame: Up to Day 13
|
Up to Day 13
|
|
Placebo-corrected change from baseline PR interval
Time Frame: Up to Day 13
|
Up to Day 13
|
|
Change from baseline QRS interval
Time Frame: Up to Day 13
|
Up to Day 13
|
|
Placebo-corrected change from baseline QRS interval
Time Frame: Up to Day 13
|
Up to Day 13
|
|
Number of participants with categorical outliers for QTcF
Time Frame: Up to Day 13
|
Up to Day 13
|
|
Number of participants with categorical outliers for HR
Time Frame: Up to Day 13
|
Up to Day 13
|
|
Number of participants with categorical outliers for PR interval
Time Frame: Up to Day 13
|
Up to Day 13
|
|
Number of participants with categorical outliers for QRS interval
Time Frame: Up to Day 13
|
Up to Day 13
|
|
Number of participants with treatment-emergent changes of electrocardiogram (ECG) morphology
Time Frame: Up to Day 13
|
Up to Day 13
|
|
Change from baseline QTcF (ΔQTcF)
Time Frame: Up to Day 13
|
Up to Day 13
|
|
Number of participants with non-serious adverse events (AEs)
Time Frame: Up to approximately 17 weeks
|
Up to approximately 17 weeks
|
|
Number of participants with Serious AEs (SAEs)
Time Frame: Up to approximately 17 weeks
|
Up to approximately 17 weeks
|
|
Number of participants with AEs leading to study intervention discontinuation
Time Frame: Up to approximately 17 weeks
|
Up to approximately 17 weeks
|
|
Number of participants with vital sign abnormalities
Time Frame: Up to approximately 17 weeks
|
Up to approximately 17 weeks
|
|
Number of participants with clinical laboratory assessment abnormalities
Time Frame: Up to approximately 17 weeks
|
Up to approximately 17 weeks
|
|
Number of participants with 12-lead ECG abnormalities
Time Frame: Up to approximately 17 weeks
|
Up to approximately 17 weeks
|
|
Number of participants with physical examination abnormalities
Time Frame: Up to approximately 17 weeks
|
Up to approximately 17 weeks
|
|
Maximum observed concentration (Cmax)
Time Frame: Up to Day 13
|
Up to Day 13
|
|
Time of maximum observed concentration (Tmax)
Time Frame: Up to Day 13
|
Up to Day 13
|
|
Area under the concentration-time curve in 1 dosing interval (AUC[TAU])
Time Frame: Up to Day 13
|
Up to Day 13
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IM027-1055
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.